# Agenda

Format

The meeting will be chaired and moderated by Professor Philip Scheltens chair of World Dementia Council, Professor Emeritus at Amsterdam University Medical Centers and head of the EQT Life Sciences Dementia Fund. It will be a series of sessions beginning with diagnosis through treatments to our ultimate goal of prevention. Each session will have short introductions from panelists and will be followed up by a open mic discussion moderated by Professor Scheltens.

0830 Registration | *coffee will be served*

0900 Welcome

Welcome to the day and scene setting

Speakers

Lenny Shallcross
Executive Director
World Dementia Council

Philip Scheltens
Chair World Dementia Council
and summit host

0915 Morning sessions | *30 minute coffee break mid morning*

1 *Session one* | **Clinical meaningfulness**

There is no single interpretation of clinical meaningfulness from the clinician's standpoint, from the scale standpoint and also from the patient and carer's standpoint. There is no resolute answer and no one single measure of clinical meaningfulness that will encompass this diversity. This session will explore the different perspectives and the implications this has on treatment approval.

Speakers

Professor John Harrison
Chief Scientific Officer
Scottish Brain Sciences

Professor Gillian Leng
The Dean for the Royal Society
of Medicine former CEO of NICE

Professor Mark McClellan
Dukes University.
Former Director of FDA

Dr William Reichman
President & CEO
of Baycrest Health

2 *Session two* | **Equity**

This session will address the impact of developments in biomarkers, technology and treatments, pharmacological and non-pharmacological will have on dementia research, diagnosis, health and social care. We know from disease areas that treatments and innovation more broadly can increase inequity. Dementia diagnosis and care today is already very unequal between countries and within them. Is it inevitable over the decade ahead we will see greater inequity? Or is it possible, practical and desirable for policy makers, civil society, and the dementia community to both deliver new ways of diagnosing, treating and preventing disease and simultaneously reducing inequity?

Speakers

Howard Bergman
MD, FCFP, FRCPC, FCAHS Assistant Dean,
International Affairs, Faculty of Medicine &
Health Sciences; Professor of Family Medicine,
Medicine & Oncology and the Institute for
Health and Social Policy, McGill University

Dr Tarun Dua
Lead for Brain Health
World Health Organization

Professor Ricardo Allegri
Director of the Ageing and Memory Centre
Fleni Neurological Institute

Paola Barbarino
CEO Alzheimer's Disease International

---

3 | Session three | **Biomarkers, where do we stand?**

This session will focus on the development of biomarkers (there is a subsequent session on when to diagnoses and the questions around that). Digital, plasma and blood in AD and other forms of dementia. Where we think we will be in five or ten years, and cover some of the problems the field needs to be addressed to get there.

Speakers

Professor Karen Duff
Director UK Dementia Research Institute

Brad O'Connor
Chief Executive Cogstate

Dr Ivonne Suridjan
Director Global Clinical Development &
& Neurology Indication Leader,
Roche Diagnostics Ltd

Professor Charlotte Teunissen
Head of the Neurology Lab
Amsterdam University Medical Center

Provost Professor Arthur Toga
Provost Professor of Ophthalmology,
Neurology, Psychiatry and the Behavioual
Sciences, University of Southern California

1230 **Lunch**

1330 **Afternoon sessions** | *coffee break mid afternoon*

4 | Session four | **A timely diagnosis**

This session will follow on directly from a discussion on development of biomarkers and will focus on when and why we should diagnose someone, now and in the years ahead. From an individual and a public policy standpoint when in the development of the disease we want to diagnose someone. Practically and ethically, what is possible?

Speakers

Fiona Carragher
Director of Research and Influencing
Clinical Alzheimer's Society

Professor Giovanni Frisoni
Clinical Neurologist,
Full Professor of Neuroscience,
Geneva University Hospitals

Phyllis Ferrell
Head of Global Engagement
for AD, Eli Lilly

Jetske van der Schaar
PhD Student Amsterdam University
Medical Center

5 | Session five | **Post diagnosis in an era of treatments**

This session will consider the impact of treatments and technology (particularly data) will impact on the way health and social care systems interact with someone with dementia and their caregiver. For many today the health and social care system is a challenge. Recognising this we don't want the session to critique the current system challenges, or address what good looks like, but rather to consider the impact treatments and technology and the ageing society will have on the way care is delivered.

Speakers

Professor Alistair Burns CBE
Professor of Old Age Psychiatry NHS England
NHS England Dementia Lead

Laurence Geller CBE
Chancellor, University of West London

Ernst van Koesveld
Director General Long-Term Care,
Government of Netherlands

Professor Anja Leist
Associate Professor in Public Health &
Ageing; Vice-Head, Institute for Research
on Socio-Economic Inequality, University
of Luxembourg; Co-Chair of World Young
Leaders in Dementia (WYLD)

Dr Andrew Trister
Deputy Director, Health Artificial
Intelligence, Bill & Melinda Gates Foundation

6 Session six | The case for prevention interventions?

We will conclude the conversation with session on preventing disease, beginning with non-pharmacological interventions. Across clinical medicine there is a recognition that to manage future health care demands we have to get much better at primary and secondary disease, alongside early diagnosis. Few countries have a structure to deliver prevention (or early diagnosis) and health systems are geared to incentivise activity not outcomes. To manage an ageing population people need to take greater responsibility for their health. To what extent can dementia incentivise people to do that? And to what extent can health systems deploy interventions, particularly in later life, that are backed by robust scientific validation?

Speakers

Matthew Baumgart
Senior Director of PublicPolicy
for the Alzheimer's Association

Professor Johannes Streffer
Chief Medical Officer AC Immune

Professor Miia Kivipelto
Professor in Clinical Geriatrics,
Karolinska Institutet

George Vradenburg
Founding Chairman, Davos Alzheimer's Collaborative (DAC); Convener, Global CEO Initiative in Alzheimer's (CEOi); Chairman, Global Alzheimer's Platform Foundation (GAP) Chairman and Co-Founder of UsAgainstAlzheimer's (UsA2); Founding Member, World Dementia Council; Founding Member, US NAPA Advisory Council

7 Session seven | The development of future treatments

This session will consider what the landscape for future treatments looks like: new combination therapies, new targets and new methods of delivery. There remains a significant need to improve the understanding of basic science and to accelerate the development of trials and the speed of treatments coming to market. Data offers huge potential, but funding is also important. This session will conclude the day and hopefully draw on all of the discussion that has taken place.

Speakers

Dr Heather Snyder
Vice President Medical & Scientific
Relations Alzheimer's Association

Dr Howard Fillit
Co-Founder & Chief Science Officer of the
Alzheimer's Drug Discovery Foundation

Dr Stacie Weninger
President, FBRI

Professor Caleb Webber
Director of Informatics,
UK Dementia Research Institute

Dr Laurence Barker
Partner Dementia Discovery Fund

1700 Closing session

Speakers

George Freeman
Minister for Science, Research
and Innovation, UK Government

Professor Philip Scheltens
Chair World Dementia Council
and summit host

Lenny Shallcross
Executive Director
World Dementia Council

1730 Drinks reception